We demonstrate the key role of KIRREL in tumour progression and speculate that it might promote tumour cell proliferation and angiogenesis by activating the PI3K/AKT/mTOR pathway, revealing KIRREL as a potential target for GC therapy. This evidence concerns the gene AKT1 and gastric cancer.